milnacipran has been researched along with paroxetine in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.50) | 18.7374 |
| 1990's | 1 (2.50) | 18.2507 |
| 2000's | 26 (65.00) | 29.6817 |
| 2010's | 12 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Baba, S; Horisawa, T; Kato, T; Kinomura, N; Kodo, T; Koyama, K; Masumoto, S; Matsumoto, K; Matsumoto, Y; Oki, H; Yabuuchi, K; Yoshinaga, H | 1 |
| Briley, M; Moret, C | 1 |
| Barone, P; Briley, M; Fillion, G; Moret, C | 1 |
| Barbagli, B; Boissard, R; Fort, P; Gervasoni, D; Henninot, V; Luppi, PH; Panconi, E | 1 |
| Koyama, T; Suzuki, K | 1 |
| Arita, S; Morishita, S | 5 |
| Nakamura, J; Okamoto, K; Shinkai, K; Ueda, N; Yoshimura, R | 1 |
| Hemrick-Luecke, SK; Iyengar, S; Simmons, RM; Webster, AA; Xu, JY | 1 |
| Cabanac, F; Pezous, N; Sechter, D; Tournoux, A; Vandel, P; Weiller, E | 1 |
| Cabanac, F; Panconi, E; Pezous, N; Sechter, D; Tournoux, A; Vandel, P; Weiller, E | 1 |
| Bourin, M; Hascoët, M; Massé, F | 1 |
| Nakamura, J; Shinkai, K; Toyohira, Y; Tsutsui, M; Ueno, S; Yanagihara, N; Yoshimura, R | 2 |
| Inoue, Y; Iwakawa, M; Kojima, H; Nakajima, M; Nakamura, J; Okamoto, T; Shinkai, K; Soya, A; Terao, T; Ueta, Y; Yoshimura, R | 1 |
| Ikeda, K; Kobayashi, T; Washiyama, K | 1 |
| Hori, H; Mitoma, M; Nakamura, J; Okamoto, T; Sugita, A; Ueda, N; Umene, W; Yoshimura, R | 1 |
| Nomura, S; Sato, Y; Shigemura, J; Yoshino, A | 1 |
| Baldwin, D; Briley, M; Moreno, RA | 1 |
| Hori, H; Kodama, Y; Nakamura, J; Nakano, H; Sugita, A; Ueda, N; Umene, W; Yoshimura, R | 1 |
| Azuma, J; Fukuda, T; Hosoi, Y; Kato, M; Kinoshita, T; Nonen, S; Okugawa, G; Takekita, Y; Wakeno, M; Yamashita, M | 1 |
| Awa, Y; Hattori, T; Ito, T; Sakakibara, R; Uchiyama, T; Yamaguchi, C | 1 |
| Abe, H; Ikeda, T; Ishida, Y; Nakamura, T; Naono, R; Nishimori, T; Takeda, R | 1 |
| Chang, TT; Chen, YC; Lee, SY; Lêng, CH; Lu, RB; Wang, YS; Wu, JY | 1 |
| Aburakawa, Y; Aizawa, H; Hasebe, N; Kwak, S; Sawada, J; Yamashita, T | 1 |
| Hori, H; Ikenouchi-Sugita, A; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R | 1 |
| Imai, S; Kuzumaki, N; Narita, M; Rahmadi, M; Suzuki, T; Yamashita, A | 1 |
| Nagata, T; Nakajima, T; Teo, AR; van Vliet, I; Yamada, H; Yoshimura, C | 1 |
| Azuma, J; Hasegawa, R; Hiratsuka, K; Ishiwata, K; Kato, M; Kinoshita, T; Kurosawa, T; Kurose, K; Nishikawa, J; Nonen, S; Okugawa, G; Saito, Y; Wakeno, M | 1 |
| Chang, YH; Chen, PS; Chen, SH; Chen, SL; Cheng, LY; Chu, CH; Chuang, HY; Lee, IH; Lu, RB; Wang, YS; Yang, YK; Yeh, TL | 1 |
| Azuma, J; Kato, M; Kinoshita, T; Nonen, S; Serretti, A; Takekita, Y; Wakeno, M | 1 |
| Egashira, N; Kuwahara, J; Masuda, S; Ueda, M; Ushio, S; Yamada, T; Zukeyama, N | 1 |
| Harada, S; Matsuura, W; Tokuyama, S | 1 |
| Dudka, J; Poleszak, E; Serefko, A; Stasiuk, W; Świąder, K; Szopa, A; Wlaź, P; Wyska, E | 1 |
2 review(s) available for milnacipran and paroxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Pharmacokinetics and drug interaction of antidepressants and anti-manic drugs].
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Antimanic Agents; Carbamazepine; Cyclopropanes; Cytochrome P-450 Enzyme System; Drug Interactions; Fluvoxamine; Humans; Isoenzymes; Lithium; Milnacipran; Paroxetine; Selective Serotonin Reuptake Inhibitors; Valproic Acid | 2003 |
12 trial(s) available for milnacipran and paroxetine
| Article | Year |
|---|---|
Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Chi-Square Distribution; Cohort Studies; Cyclopropanes; Depression; Female; Fluvoxamine; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Psychiatric Status Rating Scales; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2004 |
A comparative study of milnacipran and paroxetine in outpatients with major depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Ambulatory Care; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Psychomotor Disorders; Reaction Time; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2004 |
Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Cyclopropanes; Depressive Disorder; Double-Blind Method; Follow-Up Studies; Humans; Milnacipran; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Treatment Outcome | 2004 |
Effects of repeated milnacipran administration on brain serotonergic and noradrenergic functions in healthy volunteers.
Topics: Adrenergic Uptake Inhibitors; Adrenocorticotropic Hormone; Adult; Brain; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Milnacipran; Norepinephrine; Paroxetine; Reference Values; Selective Serotonin Reuptake Inhibitors; Serotonin; Time Factors | 2006 |
Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Cyclopropanes; Depressive Disorder; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors | 2007 |
Resolution of sexual dysfunction during acute treatment of major depression with milnacipran.
Topics: Adult; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Sexual Dysfunctions, Psychological; Surveys and Questionnaires | 2008 |
The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Alleles; Antidepressive Agents; Asian People; Cyclopropanes; Depressive Disorder, Major; Female; Gene Expression Regulation; Humans; Japan; Male; Middle Aged; Milnacipran; Paroxetine; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptors, Adrenergic, alpha-2; Time Factors | 2008 |
Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Cyclopropanes; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Prospective Studies; Quality of Life; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urodynamics | 2008 |
Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan.
Topics: Adolescent; Adult; Aged; Asian People; Cyclopropanes; Depressive Disorder, Major; Follow-Up Studies; Humans; Middle Aged; Milnacipran; Molecular Structure; Paroxetine; Taiwan | 2008 |
Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine.
Topics: Adult; Aged; Antidepressive Agents; Blood Platelets; Case-Control Studies; Cyclopropanes; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; Male; Middle Aged; Milnacipran; Nitric Oxide; Paroxetine; Statistics as Topic; Time Factors | 2009 |
Venlafaxine, paroxetine and milnacipran for major depressive disorder: a pragmatic 24-week study.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs.
Topics: Age Factors; Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclopropanes; Depressive Disorder, Major; Female; Fibroblast Growth Factors; Fluvoxamine; Humans; Japan; Male; Middle Aged; Milnacipran; Paroxetine; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT1A; Receptors, Adrenergic, alpha-2; Serotonin Plasma Membrane Transport Proteins; Sex Factors; Treatment Outcome | 2015 |
26 other study(ies) available for milnacipran and paroxetine
| Article | Year |
|---|---|
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
Topics: Animals; Antidepressive Agents; Cytochrome P-450 CYP2D6 Inhibitors; Dioxanes; Drug Partial Agonism; Humans; Male; Piperidines; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT1 Receptor Agonists; Serotonin Plasma Membrane Transport Proteins | 2017 |
High- and low-affinity binding of [3H]imipramine in rat hypothalamus.
Topics: Amitriptyline; Animals; Citalopram; Clomipramine; Cyclopropanes; Hypothalamus; Imipramine; Kinetics; Male; Milnacipran; Paroxetine; Piperidines; Propylamines; Rats; Rats, Inbred Strains; Serotonin; Sodium | 1986 |
Autoradiographic characterization of binding sites for [3H]milnacipran, a new antidepressant drug, and their relationship to the serotonin transporter in rat brain.
Topics: 5,7-Dihydroxytryptamine; Animals; Autoradiography; Benzylamines; Binding Sites; Binding, Competitive; Biological Transport; Brain; Brain Chemistry; Cyclopropanes; Milnacipran; Paroxetine; Rats; Rats, Wistar; Serotonin Receptor Agonists; Tritium | 1994 |
Effect of chronic treatment with milnacipran on sleep architecture in rats compared with paroxetine and imipramine.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Animal; Body Weight; Cyclopropanes; Imipramine; Male; Milnacipran; Paroxetine; Rats; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep Stages; Sleep, REM; Wakefulness | 2002 |
Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
Topics: Antidepressive Agents; Bipolar Disorder; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Milnacipran; Outpatients; Paroxetine; Psychiatric Status Rating Scales; Retrospective Studies; Time Factors; Treatment Outcome | 2003 |
Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Cohort Studies; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Personality Inventory; Psychometrics; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sex Factors; Treatment Outcome | 2003 |
Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment.
Topics: Adult; Aged; Biomarkers; Cyclopropanes; Depressive Disorder; Female; Homovanillic Acid; Hospitals, University; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Milnacipran; Paroxetine; Patient Selection; Selective Serotonin Reuptake Inhibitors | 2004 |
Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
Topics: Acute Disease; Amines; Amitriptyline; Animals; Conscious Sedation; Cyclohexanecarboxylic Acids; Cyclohexanols; Cyclopropanes; Disease Models, Animal; Drug Therapy, Combination; Duloxetine Hydrochloride; Fluoxetine; Formaldehyde; Gabapentin; gamma-Aminobutyric Acid; Male; Methyltyrosines; Milnacipran; Neuromuscular Junction; Norepinephrine; p-Chloroamphetamine; Pain; Paroxetine; Rats; Rats, Sprague-Dawley; Serotonin; Thiophenes; Venlafaxine Hydrochloride | 2004 |
Prevalence of induced mania in patients treated with milnacipran: a comparison with paroxetine.
Topics: Adult; Aged; Bipolar Disorder; Cohort Studies; Cyclopropanes; Depression; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Prevalence; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires | 2004 |
Differential effects of milnacipran, fluvoxamine and paroxetine for inhibited and agitated depression.
Topics: Cohort Studies; Cyclopropanes; Depression; Drug Administration Schedule; Fluvoxamine; Humans; Milnacipran; Paroxetine; Psychomotor Agitation; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires | 2004 |
alpha2-Adrenergic agonists antagonise the anxiolytic-like effect of antidepressants in the four-plate test in mice.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Citalopram; Clonidine; Cyclohexanols; Cyclopropanes; Dose-Response Relationship, Drug; Drug Antagonism; Guanabenz; Male; Mice; Milnacipran; Motor Activity; Paroxetine; Punishment; Selective Serotonin Reuptake Inhibitors; Statistics, Nonparametric; Venlafaxine Hydrochloride | 2005 |
Effect of prolonged exposure to milnacipran on norepinephrine transporter in cultured bovine adrenal medullary cells.
Topics: Adrenal Medulla; Adrenergic Uptake Inhibitors; Animals; Cattle; Cells, Cultured; Cycloheximide; Cyclopropanes; Dactinomycin; Desipramine; Gene Expression Regulation; Milnacipran; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; RNA, Messenger; Up-Regulation | 2005 |
Inhibition of G protein-activated inwardly rectifying K+ channels by the antidepressant paroxetine.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Second-Generation; Barium; Cyclopropanes; Electrophysiology; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Hydrogen-Ion Concentration; Milnacipran; Oocytes; Paroxetine; Plasmids; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Receptor, Adenosine A1; Reverse Transcriptase Polymerase Chain Reaction; Selective Serotonin Reuptake Inhibitors; Trazodone; Xenopus laevis | 2006 |
Stimulation of catecholamine synthesis via activation of p44/42 MAPK in cultured bovine adrenal medullary cells by milnacipran.
Topics: Adrenal Medulla; Animals; Antidepressive Agents; Butadienes; Catecholamines; Cattle; Cells, Cultured; Cyclopropanes; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Enzyme Activation; Fluvoxamine; Milnacipran; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitriles; Paroxetine; Phosphorylation; Protein Kinase Inhibitors; Selective Serotonin Reuptake Inhibitors; Time Factors; Tyrosine; Tyrosine 3-Monooxygenase | 2007 |
Patient satisfaction with antidepressants: an Internet-based study.
Topics: Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclopropanes; Data Collection; Depressive Disorder, Major; Fluvoxamine; Humans; Internet; Japan; Logistic Models; Milnacipran; Paroxetine; Patient Satisfaction; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires | 2008 |
Two cases of burning mouth syndrome treated with olanzapine.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Burning Mouth Syndrome; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Milnacipran; Olanzapine; Paroxetine; Treatment Outcome | 2008 |
Effects of intrathecal administration of newer antidepressants on mechanical allodynia in rat models of neuropathic pain.
Topics: Analgesics; Animals; Antidepressive Agents; Cyclopropanes; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Animal; Fluvoxamine; Hyperalgesia; Injections, Spinal; Male; Milnacipran; Pain Threshold; Paroxetine; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Sciatic Neuropathy; Selective Serotonin Reuptake Inhibitors; Serotonin; Spinal Cord | 2009 |
Effects of antidepressants on GluR2 Q/R site-RNA editing in modified HeLa cell line.
Topics: Adenosine Deaminase; Amitriptyline; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Arginine; Cyclopropanes; Desipramine; Fluoxetine; Fluvoxamine; Glutamine; HeLa Cells; Humans; Imipramine; Milnacipran; Morpholines; Paroxetine; Reboxetine; Receptors, AMPA; RNA Editing; RNA-Binding Proteins; RNA, Messenger | 2009 |
Sleep disturbance associated with an enhanced orexinergic system induced by chronic treatment with paroxetine and milnacipran.
Topics: Animals; Brain; Cyclopropanes; Electroencephalography; Electromyography; Histamine; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Milnacipran; Neuropeptides; Orexin Receptors; Orexins; Paroxetine; Receptors, Histamine; Receptors, Neuropeptide; Reverse Transcriptase Polymerase Chain Reaction; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep Wake Disorders; Synaptic Transmission | 2011 |
Comorbid social withdrawal (hikikomori) in outpatients with social anxiety disorder: clinical characteristics and treatment response in a case series.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclopropanes; Diagnostic and Statistical Manual of Mental Disorders; Female; Fluvoxamine; Humans; Interview, Psychological; Japan; Male; Milnacipran; Obsessive-Compulsive Disorder; Paroxetine; Phobic Disorders; Psychotherapy, Group; Reactive Attachment Disorder; Retrospective Studies; Social Isolation; Treatment Outcome; Young Adult | 2013 |
Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Asian People; Cohort Studies; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Genome-Wide Association Study; Genotype; GPI-Linked Proteins; Humans; Male; Middle Aged; Milnacipran; Neural Cell Adhesion Molecules; Paroxetine; Polymorphism, Single Nucleotide; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological | 2012 |
Comparison of the Anti-tumor Effects of Selective Serotonin Reuptake Inhibitors as Well as Serotonin and Norepinephrine Reuptake Inhibitors in Human Hepatocellular Carcinoma Cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Citalopram; Cyclopropanes; Duloxetine Hydrochloride; Fluvoxamine; Hep G2 Cells; Humans; Liver Neoplasms; Milnacipran; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline | 2015 |
Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia.
Topics: Amines; Analgesics; Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressive Agents, Tricyclic; Brain Ischemia; Carbamazepine; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Cyclopropanes; Gabapentin; gamma-Aminobutyric Acid; Hyperalgesia; Imipramine; Indomethacin; Male; Mexiletine; Mice; Milnacipran; Morphine; Neuralgia; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2016 |
Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Brain; Bupropion; Chromatography, High Pressure Liquid; Cyclopropanes; Depressive Disorder; Desipramine; Disease Models, Animal; Drug Interactions; Excitatory Amino Acid Antagonists; Injections, Intraperitoneal; Male; Mice; Milnacipran; Motor Activity; Paroxetine; Piperidines; Receptors, N-Methyl-D-Aspartate | 2017 |